Martin Reck, MD, PhD, of LungenClinic, discusses results from the IMpower133 study of carboplatin plus etoposide with or without atezolizumab in patients with untreated extensive-stage small cell lung cancer (Abstract OA11.06).
Martin Reck, MD, PhD, of the LungenClinic, discusses the results from KEYNOTE-799, which explored a new strategy to increase the intensity of treatment in patients with unresectable, locally advanced, stage III non–small cell lung cancer (Abstract OA02.03).
Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, invites his colleagues to enroll their patients in a large prospective study, for which he serves as Principal Investigator. The study is searching for solutions for treating patients with lung cancer who also have the coronavirus, because so many experience an aggressive course of infection.
Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked to overall and progression-free survival across two immunotherapy trials, and was independent of PD-L1 status (Abstract OA01.04).
Justin F. Gainor, MD, of Massachusetts General Hospital, discusses two key phase II studies on non–small cell lung cancer: nivolumab vs nivolumab plus ipilimumab in EGFR-mutant disease and the oral selective AXL inhibitor bemcentinib with pembrolizumab in advanced disease (Abstracts OA01.06 and OA01.07).
Jill Feldman, a patient advocate and lung cancer survivor, discusses the current challenges and potential solutions to including more people of color and those in underserved communities in clinical trial research (Abstract PL04.06).
